hrp0094p2-126 | Diabetes and insulin | ESPE2021
Fowler Melissa
, Zhao Jian
, Sturchler Emmanuel
, Athanacio Jon
, Kredel Taylor
, Antwan Agnes
, Yan Claudia
, Staley Christine
, Chen Jenny
, Kusnetzow Ana Karin
, Struthers R. Scott
, Zhu Yun Fei
, Betz Stephen
, Markison Stacy
,
CRN04777 is an orally administered nonpeptide that is a potent and selective agonist of somatostatin 5 (SST5) receptors and is currently under development for the treatment of congenital hyperinsulinism (HI), the most common cause of persistent hypoglycemia in newborns and infants. Congenital HI arises from mutations within the insulin secretion pathway and is characterized by excessive and/or inappropriate insulin secretion by pancreatic islet beta cells. This excess insulin ...